Zhejiang Orient Gene Biotech (688298) Fundamentals 2026 — Revenue Analysis | SniperIQ
Zhejiang Orient Gene Biotech (688298) is a CN-listed Healthcare company in Medical - Specialties with a market capitalization of ¥3.7B, trading at ¥18.50 on the SHH. This SniperIQ fundamentals page covers Zhejiang Orient Gene Biotech's valuation, revenue (¥947M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Zhejiang Orient Gene Biotech's market cap?
Zhejiang Orient Gene Biotech (688298) has a market capitalization of approximately ¥3.7B, trading at ¥18.50 on the SHH. Market cap moves with the live share price.
How much revenue does Zhejiang Orient Gene Biotech generate?
Zhejiang Orient Gene Biotech reported revenue of ¥947M for fiscal year 2025, with net income of -¥574M and earnings per share (EPS) of -2.93. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Zhejiang Orient Gene Biotech pay a dividend?
Zhejiang Orient Gene Biotech does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Zhejiang Orient Gene Biotech a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Zhejiang Orient Gene Biotech (688298) the key facts are: market cap ¥3.7B, revenue ¥947M, 52-week range 17.03-30.65. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Zhejiang Orient Gene Biotech's full fundamentals live
Get Zhejiang Orient Gene Biotech's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.